CollPlant Biotechnologies Net Income 2017-2021 | CLGN

CollPlant Biotechnologies net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
CollPlant Biotechnologies Annual Net Income
(Millions of US $)
2020 $-6
2019 $-11
2018 $-6
2017 $-6
2016 $-8
CollPlant Biotechnologies Quarterly Net Income
(Millions of US $)
2021-06-30 $-3
2021-03-31 $10
2020-12-31 $-3
2020-09-30 $1
2020-06-30 $-2
2020-03-31 $-2
2019-12-31 $-4
2019-09-30 $-3
2019-06-30 $-1
2019-03-31 $-2
2018-12-31 $-1
2018-09-30 $-1
2018-06-30 $-2
2018-03-31 $-2
2017-12-31 $-2
2017-09-30 $1
2017-06-30 $2
2017-03-31 $1
2016-12-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.006B
CollPlant Biotechnologies Ltd. is a regenerative medicine company. It is focused on 3D bioprinting of tissues and organs, medical aesthetics and on developing and commercializing tissue repair products for orthobiologics and advanced wound care markets. CollPlant Biotechnologies Ltd., formerly knonw as CollPlant Holdings Ltd., is based in Rehovot, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48